Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma
Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
Video content above is prompted by the following:
- How do you approach sequencing bispecifics with other BCMA-targeted therapies, such as CAR T cells or antibody-drug conjugates?
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR T-cell therapies?
- Might you consider a different target
- How has the emergence of CAR T-cell therapy revolutionized your approach to sequencing different treatment classes in R/R MM?
- In what ways does the time frame of relapse—early vs late—fundamentally alter your treatment-sequencing strategies for R/R MM patients?
- What specific factors do you consider when tailoring treatment approaches for early vs late relapse?
- How do the biological and clinical characteristics of early vs late relapse influence your decision-making process?
- Discuss strategies for managing patients with high-risk cytogenetics or extramedullary disease using bispecifics.
Recent Videos
Related Content
